BRPI0909630B8 - composição em suspensão aquosa particularmente adequada para injeção dentro do olho - Google Patents

composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Info

Publication number
BRPI0909630B8
BRPI0909630B8 BRPI0909630A BRPI0909630A BRPI0909630B8 BR PI0909630 B8 BRPI0909630 B8 BR PI0909630B8 BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 B8 BRPI0909630 B8 BR PI0909630B8
Authority
BR
Brazil
Prior art keywords
particularly suitable
injection
eye
aqueous suspension
suspension composition
Prior art date
Application number
BRPI0909630A
Other languages
English (en)
Portuguese (pt)
Inventor
P Kabra Bhagwati
Sarkar Ruma
Original Assignee
Alcon Inc
Alcon Res Llc
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc, Alcon Res Llc, Alcon Res Ltd filed Critical Alcon Inc
Publication of BRPI0909630A2 publication Critical patent/BRPI0909630A2/pt
Publication of BRPI0909630B1 publication Critical patent/BRPI0909630B1/pt
Publication of BRPI0909630B8 publication Critical patent/BRPI0909630B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BRPI0909630A 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho BRPI0909630B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (3)

Publication Number Publication Date
BRPI0909630A2 BRPI0909630A2 (pt) 2015-09-22
BRPI0909630B1 BRPI0909630B1 (pt) 2019-03-26
BRPI0909630B8 true BRPI0909630B8 (pt) 2021-05-25

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909630A BRPI0909630B8 (pt) 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Country Status (21)

Country Link
US (3) US8128960B2 (enExample)
EP (1) EP2262506B1 (enExample)
JP (1) JP5581227B2 (enExample)
KR (1) KR101555293B1 (enExample)
CN (1) CN101959519B (enExample)
AR (1) AR070824A1 (enExample)
AU (1) AU2009223649B2 (enExample)
BR (1) BRPI0909630B8 (enExample)
CA (1) CA2717605C (enExample)
CL (1) CL2009000573A1 (enExample)
DK (1) DK2262506T3 (enExample)
ES (1) ES2471122T3 (enExample)
MX (1) MX2010009974A (enExample)
PL (1) PL2262506T3 (enExample)
PT (1) PT2262506E (enExample)
RU (1) RU2481842C2 (enExample)
SI (1) SI2262506T1 (enExample)
TW (1) TWI468165B (enExample)
UY (1) UY31699A1 (enExample)
WO (1) WO2009114521A1 (enExample)
ZA (1) ZA201005839B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
SI2262506T1 (sl) * 2008-03-11 2014-07-31 Alcon Research, Ltd. Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo
MX2011005586A (es) * 2008-12-22 2011-06-20 Alcon Res Ltd Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo.
CN106214321B (zh) 2010-10-15 2018-08-28 科尼尔赛德生物医学公司 用于进入眼睛的装置
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP3721872B1 (en) * 2012-11-08 2025-01-22 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
EP2991706B1 (en) 2013-05-03 2021-06-23 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
MX2016017028A (es) 2014-06-20 2017-08-07 Clearside Biomedical Inc Canula de diametro variable y metodos para el control de la profundidad de insercion para administracion de medicamentos.
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
EP3737381A4 (en) * 2018-01-10 2021-11-10 Eye Co Pty Ltd MEDICAL DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE OR CONDITION OF THE EYE
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
KR20220019667A (ko) 2019-04-16 2022-02-17 클리어사이드 바이오메디컬, 인코포레이드 주사 가능한 트리암시놀론 제형
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
WO1996020712A1 (en) 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
EP1104302A4 (en) 1998-07-10 2006-08-09 Retmed Pty Ltd PROPHYLACTIC TREATMENTS OF BLOOD VESSEL NEOFORMATION IN MACULAR DEGENERATION
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
AU2001278779A1 (en) * 2000-08-25 2002-03-04 Senju Pharmaceutical Co. Ltd. Aqueous suspension preparations
CN1553804A (zh) * 2001-07-09 2004-12-08 用于炎性疾病治疗的联合形式
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
MXPA05008561A (es) 2003-02-20 2005-11-04 Alcon Inc Uso de esteroides para tratar personas que sufren de trastornos oculares.
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
EP1663144A1 (en) * 2003-09-23 2006-06-07 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CN1905856A (zh) * 2003-12-23 2007-01-31 阿尔扎公司 用于增加受控递送的药物组合物的溶解度的方法和剂型
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1752152A4 (en) 2004-05-31 2011-02-16 Senju Pharma Co MEANS FOR VISUALIZING TRANSPARENT WEAVE
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
CA2588433A1 (en) 2004-11-17 2006-05-26 Michael R. Robinson Steroid formulation and methods of treatment using same
CN101119733A (zh) * 2005-02-18 2008-02-06 参天制药株式会社 减轻或避免甾族化合物副作用的方法
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
SI2262506T1 (sl) * 2008-03-11 2014-07-31 Alcon Research, Ltd. Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo

Also Published As

Publication number Publication date
JP2011513492A (ja) 2011-04-28
AR070824A1 (es) 2010-05-05
TW200940071A (en) 2009-10-01
CN101959519A (zh) 2011-01-26
AU2009223649B2 (en) 2013-08-29
US20120116216A1 (en) 2012-05-10
BRPI0909630A2 (pt) 2015-09-22
US20090233890A1 (en) 2009-09-17
UY31699A1 (es) 2009-05-29
AU2009223649A1 (en) 2009-09-17
PL2262506T3 (pl) 2014-09-30
MX2010009974A (es) 2010-09-30
PT2262506E (pt) 2014-06-24
CA2717605A1 (en) 2009-09-17
DK2262506T3 (da) 2014-06-10
HK1146464A1 (en) 2011-06-10
EP2262506B1 (en) 2014-05-07
US20120115829A1 (en) 2012-05-10
CN101959519B (zh) 2013-03-20
KR20100127267A (ko) 2010-12-03
WO2009114521A1 (en) 2009-09-17
KR101555293B1 (ko) 2015-10-06
SI2262506T1 (sl) 2014-07-31
TWI468165B (zh) 2015-01-11
RU2481842C2 (ru) 2013-05-20
US8211880B2 (en) 2012-07-03
ES2471122T3 (es) 2014-06-25
EP2262506A1 (en) 2010-12-22
US8128960B2 (en) 2012-03-06
RU2010141542A (ru) 2012-04-20
BRPI0909630B1 (pt) 2019-03-26
CA2717605C (en) 2012-05-15
CL2009000573A1 (es) 2010-01-04
JP5581227B2 (ja) 2014-08-27
ZA201005839B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
BRPI0909630B8 (pt) composição em suspensão aquosa particularmente adequada para injeção dentro do olho
BR112015025576A2 (pt) formulação para óleo de transmissão para redução do consumo de combustível
BR112014003903A2 (pt) composições dentais que compreendem agentes de adição fragmentação
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
WO2015028969A3 (en) Transduction buffer
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
EA201001639A1 (ru) Композиции и способы их получения и применения
NZ751877A (en) Pertuzumab variants and evaluation thereof
GB201020193D0 (en) Glucan compositions
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BRPI0911907B8 (pt) processo para produzir uma composição contendo triptofano e composição proteica contendo triptofano
MX362530B (es) Composiciones de acido hialuronico que comprenden mepivacaina.
BR112015012972A2 (pt) método para tratar uma formação subterrânea, composição para tratamento de uma formação subterrânea, e, método para preparo de uma composição aquosa para tratamento de uma formação subterrânea
EP4327880A3 (en) Solid state form of ribociclib succinate
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112015001728B8 (pt) composições de condicionador
BR112017023720A2 (pt) formulações de inibidor de corrosão
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
BR112015009301A2 (pt) biocontrole de nematoides
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: ALCON INC. (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)